SPRC - Clearmind Medicine Submits Three Additional International Patent Applications for Innovative MDMA Ibogaine and Ketamine Compounds | Benzinga
New patent applications build upon Clearmind's broad IP protection in the psychedelic space
Vancouver, Canada, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. ((Nasdaq, CSE:CMND), (FSE: CWY0) ("Clearmind" or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced that it has submitted three additional patent applications under the international Patent Cooperation Treaty ("PCT"), as part of its ongoing collaboration with SciSparc Ltd. (NASDAQ:SPRC) ("SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system.
The patent applications refer to novel proprietary compositions of 3,4-Methylenedioxymethamphetamine (MDMA), Ibogaine, and Ketamine, each with Palmitoylethanolamide ("PEA"), the active ingredient of SciSparc's proprietary CannAmide™. These applications were previously filed as provisional patent applications with the United States Patent and Trademark Office ("USPTO").
Overall, as part of this collaboration, 8 other patent applications have been filed by Clearmind with the USPTO for various combinations, 3 of them for the combination of SciSparc's PEA with Clearmind's MEAI compound (5-methoxy-2-aminoindane) for the treatment of alcohol use disorder, treatment of cocaine addiction and treatment of obesity and its related metabolic disorders. In addition, seven patent applications were filed under the international PCT.
Dr. Adi Zuloff-Shani, Clearmind's Chief Executive Officer, stated, "These latest patent applications are expected to significantly expand our IP protection, and further enhance our leadership in the psychedelic ...